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LIST OF ABBREVIATIONS 
 
AChE  Acetylcholinesterase 
Ado  Adenosine 
AMPA α- amino-3-hydroxy-5-methylisoxazole-4-propionate 
Asp  Aspartate 
AUC  Area under the curve 
ChAT  choline Ο-acetyltransferase 
DBB  Diagonal band of Brocca 
DPCPX 1,3-dipropyl-8-cyclopentylxanthine 
Gln  Glutamine 
Glu  Glutamate 
Gly  Glycine 
KW  Kruskal-Wallis 
MK-801 Dizocilpine maleate 
MS  Medial septum 
NGS  Normal goat serum 
NSE  Neuron specific enolase 
OPA  O-phthaldialdehyde 
PBS  Phosphate buffered saline 
QNB  Quinuclidinil benzilate 
Ser  Serine 
Tau  Taurine
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ABSTRACT 
We present an overview of the long term adaptation of hippocampal neurotransmission to 
cholinergic and GABAergic deafferentation caused by excitotoxic lesion of the medial 
septum. Two months after septal microinjection of 2.7 nmol α- amino-3-hydroxy-5-
methylisoxazole-4-propionate (AMPA), a 220% increase of GABAA receptor labelling in 
the hippocampal CA3 and the hilus was evidenced, and also changes in hippocampal 
neurotransmission characterised by in vivo microdialysis and HPLC. Basal amino acid and 
purine extracellular levels were studied in control and lesioned rats. In vivo effects of 100 
mM KCl perfusion and adenosine A1 receptor blockade with 1,3-dipropyl-8-
cyclopentylxanthine (DPCPX) on their release were also investigated. In lesioned animals 
GABA, glutamate and glutamine basal levels were decreased and taurine, adenosine and 
uric acid levels increased. A similar response to KCl infusion occurred in both groups 
except for GABA and glutamate, which release decreased in lesioned rats. Only in 
lesioned rats, DPCPX increased GABA basal level and KCl-induced glutamate release, 
and decreased glutamate turnover. Our results evidence that an excitotoxic septal lesion 
leads to increased hippocampal GABAA receptors and decreased glutamate 
neurotransmission. In this situation, a coordinated response of hippocampal retaliatory 
systems takes place to control neuron excitability. 
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Neurochemical features of normal brain aging, in particular those associated with memory 
impairments and neurodegenerative diseases, have generated intense research activities 
over the last decades. As a classical model, lesions of the basal forebrain causing 
disruption of the septohippocampal pathway have consistently mimicked some of these 
impairments in cognitive processing and revealed reductions in cholinergic markers in the 
hippocampus (Waite et al. 1994; Zapata et al. 2000). However, it appears evident that age-
related alterations in brain cholinergic activity cannot fully account for all those cognitive 
deficits and that other neurotransmitters are also involved. For instance, a reduction in the 
number of GABAergic neurons located in the medial septum (MS) and the diagonal band 
of Brocca (DBB) projecting to the hippocampus also contribute to some of these cognitive 
impairments (McAlonan et al. 1995; Venero and Hefti 1998). But among all 
neurotransmitters, glutamate (Glu) is considered of special relevance given its involvement 
in memory-related phenomena, such as long-term potentiation, and its central role in 
excitotoxicity. 
The excitotoxic hypothesis of CNS injury is based on an excessive glutamate-
mediated excitation that stands out as a critical factor common to a variety of neurological 
disorders (Obrenovitch and Urenjak 1997; Obrenovitch et al. 2000; Arundine and 
Tymianski 2004). It is generally accepted that excitotoxic injury to neurons results from 
excessive inward currents of Ca2+ and Na+ through glutamate-operated ion channels, 
supplemented by release of Ca2+ from intracellular stores subsequent to metabotropic Glu 
receptor activation, leading to intracellular Ca2+ overload (Arundine and Tymianski 2004). 
Excitotoxicity also involves an imbalance of transmembrane Na+, Cl− and K+ gradients, 
cell swelling (Katayama et al. 1995) and formation of calcium precipitates in most CNS 
areas (Nitsch and Scotti 1992; Mahy et al. 1995; Robledo et al. 1999). The complexity of 
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the mechanisms involved in glutamatergic neurotransmission makes it already apparent 
that a number of abnormalities, either pre-synaptic, post-synaptic or glial, alone or in 
combination, can be excitotoxic (Obrenovitch et al. 2000). 
Given these toxic effects, adaptations that act to decrease synaptic accumulation of 
Glu can potentially be protective. A number of these protective mechanisms are conducted 
to inhibit Glu release during insults, and some of them involve retrograde signalling of 
inhibitory neurotransmitters and neuromodulators. Thus, GABA, taurine (Tau) and 
adenosine (Ado) present a retaliatory activity that has shown neuroprotective properties 
during Glu-mediated neuronal insults (see Sapolsky 2001 for a review). For example, 
GABAergic retrograde signalling in hippocampus is multisynaptic, i.e. collaterals from 
glutamatergic pyramidal terminate on GABAergic interneurons which, in turn, inhibit 
glutamatergic neurons (Saransaari and Oja 1997). Astroglial Tau release during insults 
derived from potassium and water uptake decreases presynaptic neuronal excitability by 
increasing chloride influx (Saransaari and Oja 2004). Ado neuroprotective activity is 
accomplished through binding to A1 adenosine receptors linked by G proteins to both 
calcium and potassium channels (Pearson et al. 2004). In addition, the fine adaptation of 
the Glu-glutamine (Gln) cycle to neuronal activity and suffering is important to avoid 
excessive synaptic Glu and neuronal death (García and Massieu 2003; Massieu et al. 2003; 
Ramonet et al. 2004). 
Despite the general agreement about the interdependency of all these processes to 
avoid excessive synaptic Glu, to our knowledge, the coordinated adaptation of the major 
retaliatory systems to a chronic brain lesion has not been investigated. To better 
understand these interactions in the hippocampus, we firstly characterised the α- amino-3-
hydroxy-5-methylisoxazole-4-propionate (AMPA)-induced lesion in the MS in terms of 
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neuronal and receptor modifications. Then, in vivo alterations of hippocampal amino acid 
and purine release were investigated, with especial focus on A1 receptor-mediated Ado 
modulation of excitatory and retaliatory neurotransmission. 
 
MATERIALS AND METHODS 
Materials 
AMPA, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), O-phthaldialdehyde (OPA), 
amino acids, purines, mouse monoclonal anti-parvalbumin antibody, and rabbit policlonal 
anti-neuron specific enolase (NSE) were obtained from Sigma (St. Louis, MO, USA). 
Mouse monoclonal anti-choline Ο-acetyltransferase (ChAT, EC 2.3.1.6) antibody was 
purchased from Chemicon (Temecula, CA, USA). [3H] quinuclidinil benzilate (QNB) was 
from Du Pont-NEN, [3H] dizocilpine maleate (MK-801) was from ARC (Sant Louis, MO, 
USA) and [3H]muscimol was from Amersham (Bucks, UK). CMA/12 microdialysis 
probes (membrane length 4 mm, outer diameter 0.64 mm, cut off 20 kDa) were from 
Carnegie Medicine (Sweden). 
Animals 
Adult male albino Sprague-Dawley rats (Charles River, Barcelona) weighing 
between 250-300 g were used in the experiments. They were kept on a 12 hour light/12 
hour dark cycle, and were housed with free access to food and water. Animals were 
manipulated according to the European legislation (86/609/EEC) for animal handling and 
experimentation. Procedures were approved by the Ethic Committee of the Universitat de 
Barcelona, under supervision of the Generalitat de Catalunya. All efforts were made to 
minimise animal suffering and to use only the number of animals necessary to produce 
reliable scientific data.  
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Surgery 
Rats were anaesthetised with equithesin (a mixture of chloral hydrate and sodium 
pentobarbitone; 0.3 ml/100 g body wt, i.p.), and placed on a Kopf stereotaxic frame with 
the incisor bar set at -3.3 mm. Intracerebral injections aimed at the MS were performed 
through stainless steel cannulae connected by portex tubing to a Hamilton syringe 
activated by an infusion pump (CMA/100; Carnegie Medicine, Sweden). The cannula was 
inserted at an angle of 10º to a vertical line and positioned 0.7 mm rostral to bregma, 1.1 
mm lateral, and 5 mm ventral from dura (Paxinos and Watson 1986). 
Different groups of rats received either 0.5 µl of 5.4 mM AMPA dissolved in 50 
mM phosphate buffer saline (PBS, pH 7.4) (n = 34), 50 mM PBS (sham, n = 11), or no 
treatment (n = 6). All injections were made over a period of 5 min, and the needle was left 
in place for an additional 5 min to allow for passive diffusion, and to prevent spread of the 
excitotoxin up the cannula track upon removal. The dose of AMPA was selected according 
to previous studies showing neurodegenerative processes (Ramonet et al. 2004; Rodríguez 
et al. 2004). As values from sham and non-operated rats did not significantly differ in any 
of the parameters studied, they were pooled in a group (n=17) called control. 
Microdialysis procedure 
Two months after the injection of AMPA, 40 animals (AMPA n= 28, control n= 
12) were re-anaesthetised, placed on a stereotaxic frame, and microdialysis guide cannulae 
(Carnegie Medicine) were implanted unilaterally in the ventral hippocampus (5.2 mm 
caudal to bregma, ± 4.6 mm lateral to bregma, and 2.46 mm ventral from dura). In half of 
the animals, the probes were implanted in the right hippocampus, and in the other half they 
were placed in the left hippocampus. 
8 
Twenty-four hours after implantation of the guide cannulae, CMA/12 microdialysis 
probes were inserted into the hippocampus and 12 hours later they were connected to a 
microinjection pump (KDS220, Kd Scientific, Boston, MA, USA) as previously described 
(Boatell et al. 1995). The probes were continuously perfused with artificial CSF (126.5 
mM NaCl, 2.4 mM KCl, 1.1 mM CaCl2, 0.83 mM MgCl2, 27.5 mM NaHCO3, 0.5 mM 
KH2PO4, 0.5 mM Na2SO4, and 5.8 mM glucose; pH 7.4.) at a rate of 0.2 µl/min for 12 
hours. This procedure was carried out in order to ensure stability in basal amino acid 
release, and in order to minimise astroglial reaction. Then the perfusion rate was changed 
to 2.0 µl/min and, after a 30-min washout period, samples were collected in ice-cooled 
eppendorfs every 20 min during 460 min. Half of the total amount of each sample was 
used for amino acid detection and the other half for purine detection. Samples were then 
frozen immediately and stored at -80ºC until analysis. In these conditions basal amino acid 
and purine release was similar to that described elsewhere (Boatell et al. 1995; Britton et 
al. 1996). 
All rats (AMPA n=28, control n=12) were initially perfused with CSF for 80 min 
(CSF 1), then with a high concentration of KCl (100 mM, KCl 1) for 40 min and again 
with CSF for 80 min (CSF 2). Subsequently, half of the rats (AMPA n=14, control n=6) 
were perfused with CSF for 40 min, then with 100 mM KCl for another 40 min and CSF 
for another 180 min. The other half (AMPA n=14, control n=6) were perfused with 0.1 
µM DPCPX for 40 min (DPCPX), then with KCl for 40 min (KCl 2) and CSF for another 
180 min (CSF 3). 
The DPCPX concentration chosen was in the range of A1 receptor specific 
saturation (Kaku et al. 1994; Lucchi et al. 1996) and its perfusion condition was selected to 
block the A1 receptor in basal and KCl-stimulated initial states. Six microdialysis probes 
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were selected to test the probe recovery as previously described (Ballarín et al. 1991). The 
mean relative probe recovery for each studied compound were: 24 ± 3% for aspartate 
(Asp), 25 ± 2% for GABA, 22 ± 2% for Glu, 26 ± 2% for Gln, 20 ± 2% for glycine (Gly), 
27 ± 3% for Tau, 20 ± 1% for Ado, 13 ± 1% for hypoxantine, 20 ± 2% for inosine and 50 
± 5% for uric acid. Extracellular concentrations of neurotransmitters were estimated 
according to these values. 
Amino acid and purine analysis 
Extracellular levels of Glu, Gln, GABA, Tau, Asp and Gly were analysed by HPLC 
with fluorescence detection (Waters, Barcelona, Spain), after derivatisation with OPA as 
previously reported (Boatell et al. 1995). Serine (Ser) was also included in our analysis as 
a control for non-specific changes. The content of amino acids in dialysate samples was 
quantified from peak areas using homoserine as an internal standard and a mixture of all 
the studied amino acids as external standard. The relation between peak areas and amount 
of amino acid injected was linear in the range of the dialysate sample concentrations. 
Extracellular levels of Ado, inosine, hypoxantine and uric acid were analysed by 
HPLC with ultraviolet detection (Waters, Barcelona, Spain) at 260 nm, by modification of 
previous protocols (Ballarín et al. 1995). In order to maximise the detection of Ado, two 
20-min samples were systematically pooled and directly injected on a C18 phase reverse 
column (µ-boundapack length 30 cm, 10 µm i.d.). Chromatograms were developed in 
isocratic 0.9 ml/min flow of 0.1 M Tris-HCl (pH 8.15) containing 10 % (v/v) methanol. 
The content of purines was quantified from peak areas using a mixture of all of them as 
external standard. The relation between peak areas and amount of purine injected was 
linear in the range of the dialysate sample concentrations.  
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Histochemistry and in vitro autoradiography procedures 
Two months after the injection of AMPA, 11 animals (AMPA n= 6, control n= 5) 
were used for the in vitro autoradiography studies. Rats were anaesthetised, decapitated 
and the brain quickly removed and frozen with dry ice. Sections were then obtained at the 
level of the MS (+0.7 mm to bregma) and dorsal hippocampus (-3.3 mm to bregma). 
Adjacent sections were processed for in vitro autoradiography, for immunohistochemistry 
(see below), for acetylcholinesterase (AChE, EC 3.1.1.7) histochemistry (Koelle and 
Friedenwald 1949), or for Nissl standard staining with Cresyl Violet.  
Muscarinic receptors were labelled with [3H]QNB as described elsewhere 
(Nagasawa et al. 1994). In brief, sections were incubated for 90 min in 0.015 M phosphate 
buffer (pH 7.4) containing 1 nM [3H]QNB (43 Ci/mmol). Non-specific binding was 
determined in presence of 1 µM atropine sulphate. GABAA receptor autoradiography was 
performed using [3H]muscimol as previously described (Ban et al. 1994; Schliebs et al. 
1997). In brief, after 15 min washing in an ice cold 0.05 M Tris-citrate buffer (pH 7.4) 
containing 2.5 mM CaCl2, sections were incubated for 30 min in presence of 12 nM 
[3H]muscimol (16.4 Ci/mmol) in the indicated buffer solution. The non-specific binding 
was determined by incubation with 100 µM GABA. Binding to the non-competitive site of 
the NMDA receptor complex was measured according to the procedure previously 
described (Beaton et al. 1992) and slightly modified by Petegnief et al. (1999). A 2-h 
incubation was performed in presence of 10 nM [3H]MK-801 (20 Ci/mmol), at 0-4ºC in a 
0.005 M Tris-acetate buffer (pH 7.9) containing 10 mM Gly and 10 mM Glu. The non-
specific binding was determined in the presence of 10 mM (+)-MK-801. Rinses were 
performed in ice-cold 5 mM Tris-acetate containing 5 mM CGS-19755. 
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After washes in ice-cold appropiate buffer, slides were dried under a stream of air 
and apposed to 3H-sensitive films (HyperfilmTM, Amersham) for two to six weeks. Films 
were then developed and densitometrically analysed after calibration with plastic scales 
(3H-microscales, Amersham) using a computer–assisted image analysis system 
(OPTIMAS®, BioScan Inc., Washington, USA). The average brain protein content was 
8%. For each brain, eight sections were processed for total binding and two others for non-
specific binding at both stereotaxic levels. AChE staining was densitometrically quantified 
using the same image analysis system. Morphometric evaluation was performed by 
measuring the hippocampal subfield areas in Nissl stained sections with the same image 
analysis system.   
Immunohistochemistry procedure 
Sixteen hours after microdialysis, each rat was anaesthetised and transcardially 
perfused, and then, the brains were isolated and frozen as previously described (Saura et al. 
1995; Rodríguez et al. 2004). Cryostat sections (12 µm) were obtained at the level of the 
MS (+0.7 mm to bregma), dorsal (-3.3 mm to bregma) and ventral (-5.2 mm to bregma) 
hippocampus. Adjacent sections were either stained with Cresyl Violet in order to assess 
the septal lesion, and the microdialysis probe positioning, or processed for 
immunohistochemical methods. Only those animals properly lesioned and with correctly 
implanted probes were included in the study. Four rats were eliminated because of 
incomplete lesions. Also, adjacent sections of rat brain from the autoradiography study 
were processed for immunohistochemistry.  
Immunohistochemistry was carried out by the avidin-biotin-peroxidase method. 
Sections were incubated at 4ºC separately with either, mouse monoclonal anti-parvalbumin 
diluted 1:1500 (v/v), mouse monoclonal anti-ChAT diluted 1:400 (v/v), or rabbit 
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policlonal anti-NSE diluted 1:400 (v/v) as previously described (Rodríguez et al. 2001; 
Ramonet et al. 2004). Cell counts were made at x100 magnification using an ocular grid. 
The total number of parvalbumin and ChAT-imunopositive neurons was counted in the 
MS-DBB region of all animals at the level of +0.7 mm to bregma. The border between MS 
and DBB was delimitated according to Mahy et al. (1995). NSE-imunopositive neurons 
were counted in the hippocampus at -3.3 mm to bregma. The cell numbers were corrected 
for section thickness using the method of Floderus (1944). 
Data analysis 
For each parameter, Kurtosis and Skewness moments were calculated to test the 
normal distribution of data. When normality was reached, Student’s t-test and one-way 
ANOVA, followed by the LSD post-hoc test, were performed to compare the data. 
Otherwise, values of all groups were compared using the non-parametric Mann-Whitney U 
test and Kruskal-Wallis (KW) test. For histological and in vitro autoradiography studies, 
differences between control and AMPA lesioned rats were analysed using the Student's t 
or the Mann-Whitney U tests. For the microdialysis study, the effects of the lesion on basal 
and KCl-evoked neurotransmitter release were assessed with a two-way ANOVA: 1 
between subject factor: lesion with 2 levels (AMPA and control), and 1 within subject 
factor: treatment with 2 levels (CSF, KCl). Following significant interactions, one-way 
ANOVA or KW test were used for individual comparisons. The effects of treatment with 
DPCPX on basal and KCl-evoked neurotransmitter levels in lesioned and control rats were 
evaluated with a three-way ANOVA: 1 between subject factor: lesion with 2 levels 
(AMPA and control), 1 between subject factor: DPCPX with 2 levels (CSF and DPCPX), 
and 1 within subject factor: KCl with 2 levels (CSF and KCl). Since each factor only had 2 
levels, when significant two or three-way interactions were observed, individual 
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comparisons were performed using one-way ANOVAs. In addition to extracellular 
neurotransmitter content analysis, Glu and Ado turnover were also calculated by 
estimating the Gln/Glu and Uric acid/Adenosine ratios respectively for each time point. 
Then, the area under the curve (AUC) was calculated as the summatory of the semiareas 
for each treatment in order to compare the differences between groups, which were 
assessed by performing the Student’s t test. In all cases, p < 0.05 was considered as 
significant. Results are expressed as mean ± SEM. 
 
RESULTS 
Assessment of the septal lesion 
 Two months after AMPA septal microinjection, neuronal damage was observed in 
the MS. Compared to control, cell counts showed a reduction of 70 ± 4% in ChAT-
immunopositive neurons, whereas cholinergic neurons of the horizontal limb of the DBB 
were not modified (Figure 1). Reduction in GABAergic neurons of the MS was evidenced 
by the decrease of parvalbumin-immunopositive neurons (54 ± 5%) (Figure 1). Significant 
7% AChE staining reduction was observed in the MS but not in the DBB nor lateral 
septum (data not shown).  
 This MS lesion did not induced changes in the size of the hippocampal area at –3.3 
mm to bregma, but a 14% reduction was detected at this level in the area size of CA1-CA3 
pyramidal layers with respect to control. NSE-immunopositive neuronal counts evidenced 
a discrete mean 10% neuronal loss in these layers and in granular dentate gyrus. 
Significant 6% AChE staining reduction was only observed in the pyramidal layer of the 
hippocampal CA3 (data not shown).  
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Receptor labelling by in vitro autoradiography 
[3H]muscimol specific binding showed medium levels (between 1,187 and 2,193 
fmol/mg prot) in the septal area, caudate putamen and the internal layers of frontal cortex, 
with higher values in the external layers of this last area (Figure 2). In the hippocampus, 
[3H]muscimol binding was specially low in all CA3 sublayers and the hilus, with values 
lower than 1,000 fmol/mg prot. The remaining hippocampal subfields presented medium 
[3H]muscimol binding levels. Non-specific binding was homogeneous and very low, 
representing less than 10% of the total binding. The septal area of MS-lesioned rats did not 
show any modification in the amount of [3H]muscimol binding sites with respect to 
controls. The same was true for the other brain areas studied except for the hippocampal 
formation that presented a 220% and a 198% increase in the CA3 and the hilus 
respectively (Figure 2). 
[3H]QNB binding was high (between 2,099 and 5,629 fmol/mg prot) in most brain 
areas, specially in the cerebral cortex and all hippocampal CA1 subfields. Non-specific 
binding was homogeneous and low, amounting to less than 12% of total binding in cortical 
areas. In MS-lesioned animals no significant change of [3H]QNB binding was found in any 
of the studied areas. 
Specific [3H]MK-801 binding was low (less than 1,000 fmol/mg prot) in the MS 
and the internal layers of the frontal cortex. Medium [3H]MK-801 binding levels were 
found in the lateral septum and caudate putamen, whereas high levels (more than 2,000 
fmol/mg prot) were present in the cerebral cortex and the hippocampal formation. Non-
specific binding was homogeneous and low, representing less than the 15% of the total 
binding. In MS-lesioned animals, no significant changes were found in any of the studied 
areas. 
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Extracellular hippocampal neurotransmitter levels 
 Two months after the MS lesion, hippocampal extracellular levels of GABA, Glu, 
Gln, Tau, Asp, Gly, Ser, Ado, uric acid, inosine and hypoxantine were estimated by in vivo 
microdialysis and HPLC. Negligible changes were observed in the hippocampal Ser 
extracellular concentration along the study. No lesion effect was found in the Ser basal 
level nor with the KCl and DPCPX treatments. Perfusion with CSF containing 100 mM 
KCl induced in control and lesioned rats a significative increase of all other amino acids 
and purine contents, with a 20-min delayed response for GABA, Tau, Ado and uric acid. 
Return to basal values was rapid for all compounds except for Tau, which level remained 
high for 100 min. In absence of DPCPX treatment, no differences were observed in the 
levels reached after the first and the second 100 mM KCl perfusion in any of the studied 
compounds (figure 3). 
 Extracellular hippocampal GABA basal level was 40% decreased by the MS 
deafferentation and its increase caused by 100 mM KCl infusion was 34% lower than in 
control animals (F1,24 = 8.44, p < 0.01 for AMPA effect; F1,24 = 73.89, p < 0.001 for KCl 
effect, and F1,24 = 6.15, p < 0.05 for AMPA-KCl interaction). Perfusion with 0.1 µM 
DPCPX did not modify GABA level in control rats, whereas in lesioned animals a marked 
tendency to increase that did not reach statistical significance (p < 0.57) was observed 
(Figure 3).  
 With regard to Glu, its basal level was 30% reduced and its increase after KCl 
reduced 34% by the MS lesion (F1,24 = 7.53, p < 0.01 for AMPA effect; F1,24 = 105.53, p < 
0.001 for KCl effect, and F1,24 = 4.99, p < 0.05 for AMPA-KCl interaction). Perfusion with 
0.1 µM DPCPX induced a 68% increase in the Glu basal level of control rats and this 
effect was not modified by the MS lesion (Figure 3). However, a significant interaction 
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between KCl and DPCPX treatments was observed in lesioned rats (F1,20 = 4.62, p < 0.05), 
showing a differential effect of KCl perfusion before and after 0.1 µM DPCPX. In MS 
lesioned rats, 100 mM KCl administered after DPCPX induced a higher outflow of Glu 
that took longer to recover (F1,12 = 7.80, p < 0.01). 
 Basal hippocampal Gln level was 34% decreased by the MS lesion. The KCl-
induced increase of this level was not modified by the lesion (F1,25 = 7.02, p < 0.014 for 
AMPA effect; F1,24 = 65.34, p < 0.01 for KCl effect, and no AMPA-KCl interaction). 
Perfusion with 0.1 µM DPCPX significantly increased Gln level in control (p < 0.021) and 
in lesioned rats (p < 0.012) to similar values in both groups (Figure 3). The ratio Gln/Glu 
calculated as an estimation of hippocampal Glu turnover evidenced that 0.1 µM DPCPX 
treatment produced a decrease in the AUC of Glu turnover (p<0.043) that was still present 
during the subsequent 100 mM KCl perfusion (p < 0.04) (Figure 4). 
 MS-lesion did not induced any significant effect in the hippocampal Tau basal and 
100 mM KCl-induced levels. However, when each individual time point for CSF treatment 
was compared (Figure 3) a significant increase was found in lesioned rats with respect to 
controls. Perfusion with 0.1 µM DPCPX did not modify basal nor 100 mM KCl-induced 
levels of Tau in either group. 
 Basal level of Asp in the hippocampus was not significantly different in MS-
lesioned rats (Figure 5). Perfusion with 100 mM KCl produced a similar increase in the 
concentration of extracellular Asp in both groups and 0.1 µM DPCPX did not significantly 
affect basal nor KCl-evoked levels in any of the groups. Similarly, the MS-lesion did not 
modify the Gly extracellular basal nor KCl-evoked levels in the hippocampus (Figure 5). 
Perfusion with 0.1 µM DPCPX did not modify basal levels of Gly in either group, nor 
induced changes in the levels reached during the subsequent KCl perfusion. 
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 No effect of the MS deafferentation was found in the extracellular hippocampal 
Ado levels when two-way ANOVAs were performed and the same was true for the 100 
mM KCl treatment. However, one-way ANOVAs between groups receiving a similar 
treatment revealed a 60% higher Ado basal level in lesioned rats (F1,6 = 6.07, p < 0.05) and 
a 26% increase following 100 mM KCl perfusion (F1,6 = 9.14, p < 0.05) as compared to 
control animals (Figure 5). When 0.1 µM DPCPX was applied, a 63% increase in basal 
Ado level was evidenced in the lesioned group, which was not detected in control rats. In 
addition, 100 mM KCl perfusion following DPCPX increased Ado levels a 44% with 
respect to KCl treatment in control rats, but not in lesioned animals (F1,14 = 42.58, p < 
0.001 for DPCPX effect, F1,14 = 6.13, p < 0.05 for the AMPA-DPCPX interaction and F1,14 
= 10.74, p < 0.01 for AMPA-DPCPX-KCl interaction).  
 MS lesion resulted in 71% increase of basal hippocampal uric acid level but did not 
modify the 100 mM KCl response (F1,17 = 13.32, p < 0.002 for AMPA effect; F1,17 = 17.63, 
p < 0.0006 for KCl effect, and no AMPA-KCl interaction). 0.1 µM DPCPX presented no 
significant effects on uric acid levels and the subsequent 100 mM KCl perfusion in either 
group (Figure 5). We also calculated the ratio uric acid/Ado as an estimation of 
hippocampal Ado turnover (Figure 4). MS lesion induced an increase in the AUC of Ado 
turnover in lesioned rats in basal (p<0.05) and 100 mM KCl (p < 0.02) conditions. This 
increase disappeared during the 0.1 µM DPCPX and its subsequent 100 mM KCl 
perfusion. 
In several cases, extracellular levels of hypoxantine and inosine were not detectable 
due to values of inosine and hypoxantine < 30 nM. However when they could be detected 
no significant changes were observed between groups (data not shown). 
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DISCUSSION 
 Two months after the AMPA-induced MS lesion, characterised by a significant 
decrease in cholinergic and GABAergic afferences to the hippocampus, a huge increase of 
GABAA receptor content and a discrete neuronal loss are observed in the hippocampus. 
The cholinergic deafferentation reduces the presynaptic function but not the acetylcholine 
hippocampal level, which remains unvaried (Waite et al. 1994; Zapata et al. 2000). NMDA 
receptor activation has been involved in maintaining choline availability for acetylcholine 
synthesis when choline is in short supply (Zapata et al. 2000). Thus, one of the putative 
agents for the maintenance of that level is NMDA receptor, since we here demonstrate that 
its hippocampal content is not modified by the lesion, as it happens with Gly level, a co-
agonist of the receptor. This adaptation may also involve a reduction in the degradation of 
acetylcholine, since the AChE activity is decreased in the CA3. Nevertheless, the 
excitotoxic MS-lesion also leads to a lack of KCl-induced acetylcholine release in the 
hippocampus (Waite et al. 1994; Zapata et al. 2000). This presynaptic deficit, in 
combination with the stability of the muscarinic receptor content here found, evidences a 
MS-lesion-induced dysfunction of the hippocampal cholinergic system.  
 We also demonstrate that hippocampal GABAergic neurotransmission is 
substantially reduced 2 months after the MS lesion. This reduction is accompanied by a 
similar decrease in Glu and Gln levels, whereas Tau, Ado and uric acid are increased. The 
lack of variation of Asp, Gly and Ser levels argues for the specificity of these 
modifications and suggests the presence of compensatory neurotransmitter interactions to 
control Glu activity and avoid neuronal damage. To our knowledge, this is the first study 
where Asp and Glu have a different response to brain injury, which must be taken into 
account in further studies on Asp neurotransmission.  
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 The decrease in hippocampal basal GABA level is in agreement with a tonic septal 
GABAergic input to this structure (Freund and Buzsáki 1996) whose neuronal loss is also 
supported by the decrease in KCl-stimulated GABA release observed in lesioned rats. 
Although one must consider that KCl does not mimick a purely neuronal stimulus and that 
the induced neurotransmitter release can be from a non-neuronal origin or from spreading 
depression effects. The enhanced GABAA receptor content in the CA3 layer and the hilus 
may reflect a compensatory mechanism to maintain, as possible, the functionality of this 
afferent connection. Additionally, the lack of excitatory cholinergic transmission (Zapata 
et al. 1998; Zapata et al. 2000) may also have contributed to the decrease in basal GABA 
outflow, since acetylcholine modulates GABAergic interneuronal activity through its 
action on muscarinic receptors (Freund and Buzsáki 1996), which labelling remains 
unvaried after the lesion.  
 In short-term fimbria-fornix lesions, Glu outflow from the hippocampus is 
increased (Herrera et al. 1993), indicating a prevalent action of acetylcholine over the 
GABA inhibitory effect. This Glu increase may also occur initially after the AMPA MS 
microinjection. However after the long-term deafferentation, the basal level and the KCl-
induced release of Glu are decreased, whereas the content and distribution of NMDA 
receptors remain unvaried. This neuroprotective adaptation may result from a coordinated 
response that, with time, reduces glutamatergic activity through increased Ado and Tau 
activities. As this takes place when GABAergic activity is compromised, these two 
neuromodulators would not only control basal Glu activity, but also the KCl-induced 
release in a coupled synergistic inhibitory response. As shown previously, adaptation of 
the Glu/Gln cycle with a reduction of glutaminase (EC 3.5.1.2) activity also participates in 
the reduction of synaptic Glu (Ramonet et al. 2004). In conjunction with the cholinergic 
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and GABAergic lesion, the resultant glutamatergic reduction would thus account for part 
of the cognitive impairment associated to the MS lesion, limiting for instance long-term 
potentation. The maintenance of NMDA receptors here found would reflect the intent to 
preserve this function. According to all this, cognitive studies have shown that the memory 
deficits dependent on the cholinergic system appears between 15 days (McAlonan et al. 
1995) and one month (Paban et al. 2005) after the MS lesion. As the post-lesion time 
increases new mnemonic impairments are detected, being a putative result of non-
cholinergic system decompensations (Paban et al. 2005).  
 Enhancement of Tau released from glial cells decreases presynaptic excitability by 
binding to the GABAA (O'Byrne and Tipton 2000; Louzada et al. 2004) and Gly (Mori et 
al. 2002) receptors. By means of these interactions, Tau can help maintain the 
hippocampal inhibitory tone, as also suggested by the stability of Gly levels after the MS-
lesion and the increased GABAA receptors. The enhanced hippocampal Ado level and 
turnover here described in lesioned rats may serve a neuroprotective role by inhibiting 
glutamatergic activity through binding to A1 receptors (Simpson et al. 1992; Sapolsky 
2001). In this situation, perfusion with DPCPX induced a major increase in basal Glu 
outflow, a reduction in Glu turnover, and a long-lasting increase in KCl-evoked Glu 
release. These results strongly suggest that the control exerted by Ado on basal and evoked 
Glu release through A1 receptors is necessary to avoid further excitotoxic damage when 
cholinergic and GABAergic processes are compromised. CNS response to Ado is a 
balance between A1 and A2 receptor activation, and the stimulatory effects of A2 receptors 
can be masked by activation of A1 receptors (Okada et al. 1999; Dunwiddie and Masino 
2001). Therefore, it is plausible that the increased KCl-evoked Glu release observed in our 
study with lesioned rats after DPCPX infusion could be due to the action of a new pathway 
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regulated by A2 receptors. The A type of A2 receptors are proposed not only to control Glu 
and acetylcholine release, but also to control the release of GABA and of noradrenaline, 
which are mostly insensitive to A1 receptors (reviewed by Cunha 2005). However, in 
physiological conditions the effect of A1 receptors must be prevalent in the hippocampus, 
since its density is considerably greater in this brain area (Fastbom et al. 1987; 
Svenningsson et al. 1999). With the MS lesion, this hippocampal A1 receptor density may 
even increase, an effect that also would explain the DPCPX-induced Glu increase. On the 
other hand, the increase in Glu release may also be attributed to a decreased efficacy of the 
Glu transporter system, as described one month after fimbria-fornix lesions (Ginsberg et 
al. 1996), or to an increase in astroglial consumption of Glu to render energy (Haberg et al. 
2000).  
 This Ado modulation of Glu activity also extends to the other studied systems. 
After MS lesion and following DPCPX perfusion, the extracellular concentration of 
GABA increases, reaching levels similar to those observed in control rats, suggesting an 
Ado modulation of GABA activity. This hypothesis is supported by previous data showing 
that following ischemia, Ado receptor agonists inhibit in the cortex the release of GABA 
(O'Regan et al. 1992). Furthermore, as shown in cardiovascular tissue (Andresen et al. 
1999), Ado may modulate its own extracellular level through A1 adenosine receptor 
stimulation, since DPCPX increases Ado level and normalises its enhanced turnover. In 
addition, an increased Ado turnover results in an enhancement of uric acid level. Uric acid, 
a potent antioxidant, preserves mitochondrial activity and acts as a neuroprotective agent 
against the rise in Glu-induced intracellular calcium concentration (Yu et al. 1998; Mahy 
et al. 1999). 
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 We previously demonstrated that the long term MS lesion-induced neuronal loss in 
hippocampus is apoptotic with enhancement of neuronal glycolisis. This is linked to a 
cleavage of caspase 3, non necrotic processes, and Gln/Glu cycle displacement towards 
Gln production to reduce Glu synthesis (Ramonet et al. 2004). The reduction of 
extracellular Gln in MS-lesioned animals indicates that it could be expelled to vessels to 
reduce Glu released by injured neurons (Gorovits et al. 1997). In vessels, Gln exerts a 
vasodilatory effect through nitric oxide synthesis inhibition (Matés et al. 2002). Activation 
of adenosine A1 receptors may also be involved in that Gln/Glu cycle modification through 
a modulation of Glu transport, since we observed a reduction in Glu turnover after 
perfusion with DPCPX. Activation of the apoptotic program evidenced by cleavage of 
caspase 3 requires energy consumption and underlies the neurodegenerative process 
(Nicotera et al. 1999). In this situation Glu signalling and neuronal energy metabolism are 
uncoupled and the retaliatory adaptations appear deficient. 
 In summary, we present evidence that, following long-term lesion of the MS, in the 
hippocampus, extracellular GABA levels are reduced and GABAA receptor content 
increased. Moreover, extracellular levels of Glu are decreased and blockade of A1 
adenosine receptors reverses this reduction. These results demonstrate a direct control by 
Ado on Glu neurotransmission through A1 adenosine receptor stimulation, and unveil a 
coordinated interaction between GABA, Tau and Ado systems to control neuronal 
excitability. Further experiments need to be performed in order to determine the neuronal 
and glial contribution to this interactions, and to characterise the adenosine A2A receptor 
involvement in the control of extracellular hippocampal levels of Glu and GABA.  
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FIGURE LEGENDS 
Figure 1: Number of neurons in the medial septum-diagonal band complex. Illustrative 
microphotographs of ChAT (a,b) and parvalbumin (Parv) (c,d) immunostained 
sections of control and AMPA rats. Histograms show the quantification of 
ChAT (e) and Parv (f) immunopositive cells in adjacent sections. Values are 
mean ± SEM. * p < 0.05; ** p < 0.01 different from control (Student's t-test), (n 
=12 control + 24 AMPA). Bar = 75 µm. 
Figure 2: Specific in vitro binding of [3H]muscimol to rat brain sections after long-term 
MS lesion. Distribution of the GABAA receptor labelling to rat brain sections at 
the level of MS and hippocampus of control and AMPA rats. Units are fmol/mg 
prot. (I-III) means I to III cortical layers; (IV-VI) means IV to VI cortical layers. 
*, p<0.05 related to control (Mann-Whitney U test), (n =5 control + 6 AMPA).  
Figure 3: Longitudinal study of extracellular concentrations for GABA, glutamate (Glu), 
glutamine (Gln), and taurine (Tau) in the hippocampus after the long-term MS 
lesion. Extracellular hippocampal GABA (a), Glu (b), Gln (c) and Tau (d) levels 
were assessed by in vivo microdialysis with (right column) and without (left 
column) DPCPX administration. CSF 1, KCl 1 (100 mM), CSF 2, DPCPX (0.1 
µM), KCl 2 and CSF 3 correspond to the microdialysis procedure phases (see 
for details Materials and Methods section). (n = 6 control + 14 AMPA for each 
experimental condition) * p < 0.05 different from control values at the same 
time point (Student’s t-test). 
Figure 4: Hippocampal effects of MS lesion on glutamate and adenosine turnover. 
Longitudinal study of extracellular Gln/Glu (a) and uric acid /adenosine (b) 
30 
ratios of control and lesioned rats. CSF 1, KCl 1 (100 mM), CSF 2, DPCPX (0.1 
µM), KCl 2 and CSF 3 correspond to the microdialysis procedure phases (see 
Materials and Methods section). The inset histograms correspond to the percent 
change of the area under the curve with respect to the control group (100%; 
discontinuous line) during the treatments. * p< 0.05 different from control 
(Mann-Whitney U test). 
Figure 5: Extracellular hippocampal concentrations of amino acids and purines after the 
long term MS lesion. Aspartate (a), Gly (b) Ado (c) and Uric acid (d) levels 
were assessed by in vivo microdialysis. CSF 1, KCl 1 (100 mM), CSF 2, 
DPCPX (0.1 µM), KCl 2 and CSF 3 correspond to the microdialysis procedure 
phases (see Materials and Methods section). The values for CSF 1, KCl 1 and 
CSF 2 represent pooled data of the rats dialysed in the two experimental 
conditions * p < 0.05, ** p < 0.01 different from CSF 1; # p < 0.05, ## p < 0.01 
different from control values (LSD, post-hoc test).  
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